• Monday, Jan 30, 2023
  • Last Update : 10:24 am

Study: Oxford-AstraZeneca vaccine develops antibodies in 93% recipients after 2nd dose

  • Published at 07:51 am June 27th, 2021
Vaccine campaign Bangladesh
File photo: A healthcare worker prepares to administer a dose of the Oxford University-AstraZeneca vaccine Mehedi Hasan/Dhaka Tribune

Some 308 samples were collected from doctors and employees of DMCH to conduct the study


A study has found that antibodies developed in 93% of people within two weeks of receiving two doses of the Oxford-Astrazeneca vaccine.

A press release issued on Sunday said the study was carried out by a team of researchers at the Department of Microbiology of Dhaka Medical College Hospital (DMCH) in order to determine the antibody response after administration of the vaccine.

Some 308 samples were collected from doctors and employees of DMCH to conduct the health directorate-funded study, which was conducted over five months and supervised by Prof Dr SM Shamsuzzaman, the release said.

It also said that 41% of recipients showed the presence of antibodies after four weeks of taking the first dose of the vaccine, named Covidshield.

However, after two weeks of taking the second jab, antibodies were found in 93% of the recipients, Dr Shamsuzzaman told a press briefing on Sunday morning.

Dhaka Medical College Principal Prof Dr Md Titu Miah also said that further studies will determine whether booster doses are required or not. Different studies show the antibodies may exist for anytime between one to six years.

Bangladesh started the nationwide Covid-19 vaccination program on February 7, following a pilot initiative, by administering Covishield, manufactured by the Serum Institute of India (SII).

So far, the country has received seven million Covishield doses through its contract with SII, while India gave Bangladesh 3.3 million Covidshield doses as a gift.

On April 25, however, the government suspended administering the first dose of Covishield a day after India decided to stop exporting the vaccine in order to meet its own demand following a record-breaking surge in Covid-19 deaths and cases.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail